You're heard of earnings. You've heard of non-GAAP (generally accepted accounting principles) earnings. You've heard of free cash flow. You've heard of EBITDA (earnings before interest, taxation, depreciation and amortization.) But have you heard of EBITDASO? The shareholders of United Therapeutics have. From today's report:

“We are pleased to report that United Therapeutics' revenues for the year ended December 31, 2007, totaled $210.9 million,” said Martine Rothblatt, Ph.D., United Therapeutics’ Chairman and Chief Executive Officer. “This is the sixth straight year our revenues have grown by more than 30%. Our EBITDASO (earnings before interest, taxes, depreciation, amortization and stock option expense) for the year were $85.5 million, or $4.03 per basic share.”

I promise to write a poem about EBITDASO if you, the readers, don't beat me to it.